Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIAID and NIH fund Crucell's Ebola and Marburg programme

This article was originally published in Scrip

Executive Summary

Crucellhas signed a contract with the US National Institute of Allergy and Infectious Diseases, part of theNational Institutes of Health, which will provide up to $30 million in funding to develop its multivalent filovirus vaccine to protect against both the Ebola and Marburg viruses. Crucell may receive a further $40 million if the NIH triggers certain additional options. The contract, which makes use of Crucell's AdVac vaccine technology, builds upon the existing relationship between the two parties, which signed a $16.2 million contract in 2006 for the use of live viral vectors for the design and development of a HIV vaccine (Scrip Online, October 10th, 2006).

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021306

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel